128 related articles for article (PubMed ID: 32911347)
21. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
22. Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma.
Zhang L; Guo S; Schwab JH; Nielsen GP; Choy E; Ye S; Zhang Z; Mankin H; Hornicek FJ; Duan Z
PLoS One; 2013; 8(9):e75851. PubMed ID: 24086644
[TBL] [Abstract][Full Text] [Related]
23. Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3.
Shen J; Li CD; Yang HL; Lu J; Zou TM; Wang DL; Deng M
J Clin Neurosci; 2011 Jan; 18(1):96-9. PubMed ID: 20855213
[TBL] [Abstract][Full Text] [Related]
24. [Chordomas].
Riopel C; Michot C
Ann Pathol; 2007 Feb; 27(1):6-15. PubMed ID: 17568354
[TBL] [Abstract][Full Text] [Related]
25. Intradural chordoma of the Meckel's cave: a challenging differential diagnosis.
Barresi V; Caffo M; Alafaci C; Granata F; Tuccari G
Neuropathology; 2012 Oct; 32(5):577-82. PubMed ID: 22260529
[TBL] [Abstract][Full Text] [Related]
26. Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.
Akhavan-Sigari R; Gaab MR; Rohde V; Brandis A; Tezval H; Abili M; von Eckardstein K; Ostertag H
Neurosurg Rev; 2014 Jan; 37(1):79-88. PubMed ID: 23999886
[TBL] [Abstract][Full Text] [Related]
27. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
[TBL] [Abstract][Full Text] [Related]
28. Brachyury: a diagnostic marker for the differential diagnosis of chordoma and hemangioblastoma versus neoplastic histological mimickers.
Barresi V; Ieni A; Branca G; Tuccari G
Dis Markers; 2014; 2014():514753. PubMed ID: 24591762
[TBL] [Abstract][Full Text] [Related]
29. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.
Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J
Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340
[TBL] [Abstract][Full Text] [Related]
30. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
31. Loss of SMARCB1/INI1 expression in poorly differentiated chordomas.
Mobley BC; McKenney JK; Bangs CD; Callahan K; Yeom KW; Schneppenheim R; Hayden MG; Cherry AM; Gokden M; Edwards MS; Fisher PG; Vogel H
Acta Neuropathol; 2010 Dec; 120(6):745-53. PubMed ID: 21057957
[TBL] [Abstract][Full Text] [Related]
32. New Prospects for Molecular Targets for Chordomas.
Ozair MZ; Shah PP; Mathios D; Lim M; Moss NS
Neurosurg Clin N Am; 2020 Apr; 31(2):289-300. PubMed ID: 32147018
[TBL] [Abstract][Full Text] [Related]
33. [Notochordal tumors : Benign notochordal tumors and chordomas].
Barth TFE; von Witzleben A; Möller P; Scheil-Bertram S
Pathologe; 2018 Mar; 39(2):117-124. PubMed ID: 29236139
[TBL] [Abstract][Full Text] [Related]
34. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
[TBL] [Abstract][Full Text] [Related]
35. Parosteal extra-axial chordoma of the second metacarpal bone: a case report with literature review.
Tsukamoto S; Vanel D; Righi A; Donati DM; Errani C
Skeletal Radiol; 2018 Apr; 47(4):579-585. PubMed ID: 29151144
[TBL] [Abstract][Full Text] [Related]
36. Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications.
Yamaguchi T; Imada H; Iida S; Szuhai K
Surg Pathol Clin; 2017 Sep; 10(3):637-656. PubMed ID: 28797506
[TBL] [Abstract][Full Text] [Related]
37. [Notochordal tumors: From notochord to chordoma].
Guinebretière JM; de Pinieux G
Ann Pathol; 2022 Apr; 42(3):249-258. PubMed ID: 35090767
[TBL] [Abstract][Full Text] [Related]
38. Soft tissue chordomas: a clinicopathologic analysis of 11 cases.
Lauer SR; Edgar MA; Gardner JM; Sebastian A; Weiss SW
Am J Surg Pathol; 2013 May; 37(5):719-26. PubMed ID: 23588366
[TBL] [Abstract][Full Text] [Related]
39. Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability.
Naka T; Boltze C; Samii A; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
Cancer; 2003 Nov; 98(9):1934-41. PubMed ID: 14584077
[TBL] [Abstract][Full Text] [Related]
40. Incipient chordoma: a report of two cases of early-stage chordoma arising from benign notochordal cell tumors.
Yamaguchi T; Watanabe-Ishiiwa H; Suzuki S; Igarashi Y; Ueda Y
Mod Pathol; 2005 Jul; 18(7):1005-10. PubMed ID: 15803192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
